Global Genomics Group (G3) and Illumina to Partner on Cardiovascular Genomics

Global Genomics Group (G3) and Illumina to Partner on Cardiovascular Genomics

G3's Cardiovascular Disease Biomarker and Drug Target Discovery Study (the
"GLOBAL" Study) is the Single Largest Prospective Pan-Omic Study to Employ
Whole Genome Sequencing

PR Newswire

RICHMOND, Va., and SAN DIEGO, Sept. 25, 2013

RICHMOND, Va., and SAN DIEGO, Sept. 25, 2013 /PRNewswire/ --Global Genomics
Group (G3) and Illumina, Inc. (NASDAQ: ILMN) today announced that they have
entered into a partnership to investigate novel biomarkers and biological
pathways involved in the development and diagnosis of cardiovascular diseases.
Under the terms of the agreement, Illumina will conduct whole genome
sequencing (WGS) in the GLOBAL (Genetic LOci and the Burden of Atherosclerotic
Lesions) clinical study. GLOBAL is the largest pan-omic study combining
genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics,
lipoprotein proteomics and glycomics with coronary computed tomographic (CT)
angiography, an advanced imaging technology for phenotyping that allows the
precise classification of disease in patients.

"The development and progression of conditions such as cardiovascular disease
involves poorly understood complex biological processes that require
comprehensive investigative approaches to identify new disease biomarkers and
therapeutic targets," said Szilard Voros, M.D., chief executive officer and
co-founder of G3. "This is the first study of its kind, analyzing trillions of
data points from 7,000 patients, designed to investigate the biological basis
behind the complex processes responsible for atherosclerosis. We are applying
the most advanced coronary CT angiography techniques to precisely phenotype
atherosclerotic disease, while conducting a complete pan-omic analysis in
every patient. WGS is a centerpiece of this landmark study, and this
collaboration with Illumina and its most advanced next-generation sequencing
technology is essential to the success of the program. To date we have
collected more than 2,200 samples, and we anticipate completing enrollment by
summer of 2014."

Matt Posard, senior vice president and general manager of Illumina's
Translational and Consumer Genomics business, added, "Consistent with
Illumina's strategy of partnering with clinical thought leaders, we are
excited to expand our footprint in cardiovascular genomics with G3. The GLOBAL
study will be one of the largest patient studies involving genomic sequencing
and will be the largest pan-omic WGS study Illumina has participated in to
date. The sequencing data will be a critical component in deciphering the
complexities of the development and diagnosis of atherosclerosis."

The ongoing GLOBAL study ( Identifier NCT01738828) is an
international, prospective, multi-center study recruiting up to 7,000 patients
to characterize novel disease networks and biomarkers for coronary artery
disease (CAD). The study is being funded by G3 and conducted together with
strategic partner Health Diagnostic Laboratory. Eligible patients undergo
coronary CT angiography providing an accurate and detailed examination of the
disease and disease status. This precision phenotyping is combined with a
pan-omic analysis, and the data is then analyzed utilizing specifically
developed systems biology-based bioinformatics technology for identification
of diagnostic biomarkers and potential therapeutic targets.

"The GLOBAL study will involve the collection of 22 trillion data points used
to decode the complex biology underlying atherosclerotic disease," said Tonya
Mallory, chief executive officer, president and co-founder of Health
Diagnostic Laboratory, a strategic partner of G3. "The study will represent
validation of this technology and opens the door to similar analyses of other
diseases, such as oncologic, neurodegenerative and psychiatric, with the goal
of identifying novel biomarkers and therapeutic targets for diagnosis,
prevention and treatment of these serious and debilitating diseases."

About Global Genomics Group (G3)

G3 is a life sciences company investigating biological networks that lead to
the development of disease to identify novel diagnostic biomarkers and
therapeutic targets. G3 combines precision phenotyping with pan-omics
(genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics,
lipoprotein proteomics and glycomics) and bioinformatics to investigate the
development and progression of conditions such as atherosclerosis in
cardiovascular disease.

For additional information, please visit

About Illumina

Illumina is a leading developer, manufacturer, and marketer of life science
tools and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We
also provide tools and services that are fueling advances in consumer genomics
and diagnostics. Our technology and products accelerate genetic analysis
research and its application, paving the way for molecular medicine and
ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this

G3 Contacts
Martina Schwarzkopf, Ph.D.
(212) 845-4292

Idean Marvasty
(404) 368-1554

Illumina Contacts
Rebecca Chambers
(858) 255-5243

Jennifer Temple
(858) 882-6822

SOURCE Global Genomics Group (G3); Illumina, Inc.

Press spacebar to pause and continue. Press esc to stop.